Payment overview · 2025
General Payments
$1,768.01
64 reported records · 27 companies
Healthcare provider profile · identity verified
John David Northup, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · SAVANNAH, GA · NPI 1023232527
Verified facts
What the public records show
CMS Open Payments records show John David Northup, M.D. received $1,768.01 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
Alnylam Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GIVLAARI as an associated drug or biological on 2969 records involving 2326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Givlaari by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $242.85 | 13.7% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $192.89 | 10.9% | 6 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $147.70 | 8.3% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $136.36 | 7.7% | 7 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.55 | 7.0% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $123.56 | 7.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $63.89 | 3.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.83 | 3.5% | 4 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $57.55 | 3.3% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $56.62 | 3.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.52 | 3.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.32 | 2.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.13 | 2.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.13 | 1.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.23 | 1.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $31.61 | 1.8% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $26.77 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.59 | 1.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.87 | 1.4% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.32 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.00 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.25 | 1.1% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.25 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.27 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.05 | 0.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.90 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,768.01 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $210.23 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $192.89 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $156.78 | 3 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $147.70 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $136.36 | 7 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $123.56 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $63.89 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.83 | 4 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $56.62 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.52 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.52 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.62 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $26.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.59 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.58 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 69 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | 27 |
| Alnylam Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | GIVLAARI open payments reported associated product |
CMS Open Payments — General Payments 2969 supporting records · 2326 recipient NPIs · example record 1212737073 |
Givlaari · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 349 | 106 |
| Famotidine | Famotidine | 220 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 206 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 19 |
| Gabapentin | Gabapentin | 135 | 33 |
| Lisinopril | Lisinopril | 133 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 127 | 40 |
| Simvastatin | Simvastatin | 127 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 113 | 35 |
| Losartan Potassium | Losartan Potassium | 104 | 28 |
| Trazodone Hcl | Trazodone Hcl | 104 | 28 |
| Repatha Sureclick | Evolocumab | 98 | 23 |
| Vascepa | Icosapent Ethyl | 94 | 16 |
| Linzess | Linaclotide | 85 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 27 |
| Metformin Hcl | Metformin Hcl | 81 | 30 |
| Januvia | Sitagliptin Phosphate | 79 | 16 |
| Montelukast Sodium | Montelukast Sodium | 77 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 24 |
| Omeprazole | Omeprazole | 74 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 19 |
| Alendronate Sodium | Alendronate Sodium | 72 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 24 |
| Azithromycin | Azithromycin | 69 | 48 |
| Rybelsus | Semaglutide | 69 | 19 |
| Glipizide | Glipizide | 67 | 14 |
| Tramadol Hcl | Tramadol Hcl | 67 | 15 |
| Allopurinol | Allopurinol | 66 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 60 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 54 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 23 |
| Ondansetron Odt | Ondansetron | 53 | 26 |
| Alprazolam | Alprazolam | 51 | 14 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 51 | suppressed |
| Furosemide | Furosemide | 51 | 15 |
| Ursodiol | Ursodiol | 51 | 12 |
| Carvedilol | Carvedilol | 49 | 12 |
| Buprenorphine Hcl | Buprenorphine Hcl | 47 | suppressed |
| Potassium Chloride | Potassium Chloride | 47 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Trulance | Plecanatide | 44 | 16 |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 14 |
| Nystatin | Nystatin | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 13 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 13 |
| Meloxicam | Meloxicam | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 12 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 15 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 28 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Progesterone | Progesterone, Micronized | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 18 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Givlaari | Givosiran Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,768.01 · 64 records | Novo Nordisk Inc | AMVUTTRA, BRIXADI, CAPLYTA, CREON, Cologuard Collection Kit, DUPIXENT, EOHILIA, EVENITY, IBSRELA, IQIRVO, Kerendia, LINZESS, MOUNJARO, Ozempic, PROLIA, RELISTOR, REPATHA, REXULTI, REZDIFFRA, Rybelsus, SUBLOCADE, Sucraid, TRELEGY ELLIPTA, VELSIPITY, VIVITROL, VOQUEZNA, WAKIX, Wegovy, XYOSTED, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error